Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 173

1.

Monoclonal antibodies with neutralizing activity and Fc-effector functions against the Machupo virus glycoprotein.

Amanat F, Duehr J, Huang C, Paessler S, Tan G, Krammer F.

J Virol. 2019 Dec 4. pii: JVI.01741-19. doi: 10.1128/JVI.01741-19. [Epub ahead of print]

PMID:
31801871
2.

Broadly protective human antibodies that target the active site of influenza virus neuraminidase.

Stadlbauer D, Zhu X, McMahon M, Turner JS, Wohlbold TJ, Schmitz AJ, Strohmeier S, Yu W, Nachbagauer R, Mudd PA, Wilson IA, Ellebedy AH, Krammer F.

Science. 2019 Oct 25;366(6464):499-504. doi: 10.1126/science.aay0678.

PMID:
31649200
3.

Cross-Reactive Antibodies Binding to the Influenza Virus Subtype H11 Hemagglutinin.

Strohmeier S, Amanat F, Krammer F.

Pathogens. 2019 Oct 21;8(4). pii: E199. doi: 10.3390/pathogens8040199.

4.

Immunogenicity of chimeric haemagglutinin-based, universal influenza virus vaccine candidates: interim results of a randomised, placebo-controlled, phase 1 clinical trial.

Bernstein DI, Guptill J, Naficy A, Nachbagauer R, Berlanda-Scorza F, Feser J, Wilson PC, Solórzano A, Van der Wielen M, Walter EB, Albrecht RA, Buschle KN, Chen YQ, Claeys C, Dickey M, Dugan HL, Ermler ME, Freeman D, Gao M, Gast C, Guthmiller JJ, Hai R, Henry C, Lan LY, McNeal M, Palm AE, Shaw DG, Stamper CT, Sun W, Sutton V, Tepora ME, Wahid R, Wenzel H, Wohlbold TJ, Innis BL, García-Sastre A, Palese P, Krammer F.

Lancet Infect Dis. 2019 Oct 17. pii: S1473-3099(19)30393-7. doi: 10.1016/S1473-3099(19)30393-7. [Epub ahead of print]

5.

Hemagglutinin-stalk antibody responses following trivalent inactivated influenza vaccine immunization of pregnant women and association with protection from influenza virus illness.

Dhar N, Kwatra G, Nunes MC, Cutland C, Izu A, Nachbagauer R, Krammer F, Madhi SA.

Clin Infect Dis. 2019 Sep 27. pii: ciz927. doi: 10.1093/cid/ciz927. [Epub ahead of print]

PMID:
31565750
6.

An Inactivated Influenza Virus Vaccine Approach to Targeting the Conserved Hemagglutinin Stalk and M2e Domains.

Sun W, Zheng A, Miller R, Krammer F, Palese P.

Vaccines (Basel). 2019 Sep 18;7(3). pii: E117. doi: 10.3390/vaccines7030117.

7.

Vaccination With Viral Vectors Expressing Chimeric Hemagglutinin, NP and M1 Antigens Protects Ferrets Against Influenza Virus Challenge.

McMahon M, Asthagiri Arunkumar G, Liu WC, Stadlbauer D, Albrecht RA, Pavot V, Aramouni M, Lambe T, Gilbert SC, Krammer F.

Front Immunol. 2019 Aug 21;10:2005. doi: 10.3389/fimmu.2019.02005. eCollection 2019.

8.

Monoclonal Antibody Responses after Recombinant Hemagglutinin Vaccine versus Subunit Inactivated Influenza Virus Vaccine: a Comparative Study.

Henry C, Palm AE, Utset HA, Huang M, Ho IY, Zheng NY, Fitzgerald T, Neu KE, Chen YQ, Krammer F, Treanor JJ, Sant AJ, Topham DJ, Wilson PC.

J Virol. 2019 Oct 15;93(21). pii: e01150-19. doi: 10.1128/JVI.01150-19. Print 2019 Nov 1.

PMID:
31434733
9.

Moving from Empirical to Rational Vaccine Design in the 'Omics' Era.

Sharma M, Krammer F, García-Sastre A, Tripathi S.

Vaccines (Basel). 2019 Aug 14;7(3). pii: E89. doi: 10.3390/vaccines7030089. Review.

10.

Comparative Immunogenicity of the 2014-2015 Northern Hemisphere Trivalent IIV and LAIV against Influenza A Viruses in Children.

Ang JC, Wang B, Wang JJF, Zeng PYF, Krammer F, Ward BJ, Russell ML, Loeb M, Miller MS.

Vaccines (Basel). 2019 Aug 12;7(3). pii: E87. doi: 10.3390/vaccines7030087.

11.

The neuraminidase of A(H3N2) influenza viruses circulating since 2016 is antigenically distinct from the A/Hong Kong/4801/2014 vaccine strain.

Wan H, Gao J, Yang H, Yang S, Harvey R, Chen YQ, Zheng NY, Chang J, Carney PJ, Li X, Plant E, Jiang L, Couzens L, Wang C, Strohmeier S, Wu WW, Shen RF, Krammer F, Cipollo JF, Wilson PC, Stevens J, Wan XF, Eichelberger MC, Ye Z.

Nat Microbiol. 2019 Dec;4(12):2216-2225. doi: 10.1038/s41564-019-0522-6. Epub 2019 Aug 12.

12.

Vaccination with viral vectors expressing NP, M1 and chimeric hemagglutinin induces broad protection against influenza virus challenge in mice.

Asthagiri Arunkumar G, McMahon M, Pavot V, Aramouni M, Ioannou A, Lambe T, Gilbert S, Krammer F.

Vaccine. 2019 Sep 3;37(37):5567-5577. doi: 10.1016/j.vaccine.2019.07.095. Epub 2019 Aug 6.

13.

No evidence of antigenic seniority in hemagglutinin specific antibody responses after adjuvanted pandemic 2009 influenza vaccination.

Madsen A, Azimi L, Tete S, Zhou F, Krammer F, Cox RJ, Jul-Larsen Å.

Vaccine X. 2019 Jun 20;2:100029. doi: 10.1016/j.jvacx.2019.100029. eCollection 2019 Aug 9.

14.

Extending the Stalk Enhances Immunogenicity of the Influenza Virus Neuraminidase.

Broecker F, Zheng A, Suntronwong N, Sun W, Bailey MJ, Krammer F, Palese P.

J Virol. 2019 Aug 28;93(18). pii: e00840-19. doi: 10.1128/JVI.00840-19. Print 2019 Sep 15.

PMID:
31375573
15.

A mosaic hemagglutinin-based influenza virus vaccine candidate protects mice from challenge with divergent H3N2 strains.

Broecker F, Liu STH, Suntronwong N, Sun W, Bailey MJ, Nachbagauer R, Krammer F, Palese P.

NPJ Vaccines. 2019 Jul 19;4:31. doi: 10.1038/s41541-019-0126-4. eCollection 2019.

16.

Pre-existing anti-neuraminidase antibodies are associated with shortened duration of influenza A (H1N1)pdm virus shedding and illness in naturally infected adults.

Maier HE, Nachbagauer R, Kuan G, Ng S, Lopez R, Sanchez N, Stadlbauer D, Gresh L, Schiller A, Rajabhathor A, Ojeda S, Guglia AF, Amanat F, Balmaseda A, Krammer F, Gordon A.

Clin Infect Dis. 2019 Jul 12. pii: ciz639. doi: 10.1093/cid/ciz639. [Epub ahead of print]

PMID:
31300819
17.

Characterization of swine-origin H1N1 canine influenza viruses.

Wang G, Dos Anjos Borges LG, Stadlbauer D, Ramos I, Bermúdez González MC, He J, Ding Y, Wei Z, Ouyang K, Huang W, Simon V, Fernandez-Sesma A, Krammer F, Nelson MI, Chen Y, García-Sastre A.

Emerg Microbes Infect. 2019;8(1):1017-1026. doi: 10.1080/22221751.2019.1637284.

PMID:
31287780
18.

Functional immune response to influenza H1N1 in children and adults after live attenuated influenza virus vaccination.

Islam S, Zhou F, Lartey S, Mohn KGI, Krammer F, Cox RJ, Brokstad KA.

Scand J Immunol. 2019 Oct;90(4):e12801. doi: 10.1111/sji.12801. Epub 2019 Sep 2.

PMID:
31269273
19.

Novel correlates of protection against pandemic H1N1 influenza A virus infection.

Ng S, Nachbagauer R, Balmaseda A, Stadlbauer D, Ojeda S, Patel M, Rajabhathor A, Lopez R, Guglia AF, Sanchez N, Amanat F, Gresh L, Kuan G, Krammer F, Gordon A.

Nat Med. 2019 Jun;25(6):962-967. doi: 10.1038/s41591-019-0463-x. Epub 2019 Jun 3.

20.

An HER2-Displaying Virus-Like Particle Vaccine Protects from Challenge with Mammary Carcinoma Cells in a Mouse Model.

Nika L, Cuadrado-Castano S, Asthagiri Arunkumar G, Grünwald-Gruber C, McMahon M, Koczka K, García-Sastre A, Krammer F, Grabherr R.

Vaccines (Basel). 2019 May 20;7(2). pii: E41. doi: 10.3390/vaccines7020041.

Supplemental Content

Loading ...
Support Center